“The Revelation team continues to strategically maximize its financial resources to achieve our stated objectives and advance the Gemini program,” said James Rolke, Chief Executive Officer of Revelation. “We look forward to announcing data from the Phase 1b study later this quarter and engaging with the FDA later this year to further the clinical development of Gemini and enhance shareholder value.” As of June 30, 2025, Revelation had $5.2M in cash and cash equivalents, compared to $6.5M as of December 31, 2024. The decrease in cash and cash equivalents was primarily due to cash used for operating activities. Based on current operating plans and projections, Revelation believes that its current cash and cash equivalents are sufficient to fund operations through December 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REVB:
- Revelation Biosciences completes dosing of patients in PRIME study
- Revelation Biosciences Announces Reverse Stock Split
- Upcoming Stock Splits This Week (July 7 to July 11) – Stay Invested
- Revelation Biosciences Inc trading halted, news pending
- Revelation Biosciences announces 1-for-3 reverse stock split, effective July 7